- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Oct 19, 2021
Product Development
Quick Takes: And then there were two — bluebird readies for split
Vertex’s Phase I diabetes data shine, plus United Therapeutics, Ipsen, Omeros and more
BioCentury | Oct 2, 2021
Regulation
Oct. 1 Quick Takes: Omeros’ shares dive after FDA flags ‘deficiencies’
BMS therapies head to EMA, plus bintrafusp alfa — a TGFβ story — Coherus and more
BioCentury | Aug 11, 2020
Product Development
Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline
Plus data from Omeros, PTC and a call to make mAbs accessible
BioCentury | Apr 1, 2020
Product Development
Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Dec 4, 2019
Clinical News
Omeros’ narsoplimab headed for 1H20 submission on back of readout
Items per page:
1 - 10 of 19